Plain-English translation of NCT06417190 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination treatment called trimodal therapy can work for people with an aggressive form of bladder cancer that has unusual cell types mixed in with standard cancer cells. Trimodal therapy combines three approaches: a procedure to remove the tumor, chemotherapy, and radiation therapy — all working together to try to save your bladder instead of requiring surgical removal.
Most aggressive bladder cancers are treated by surgically removing the entire bladder, which dramatically changes a patient's quality of life. This trial exists because there is very limited research on whether the new treatment approach can work effectively for people whose bladder cancer has these unusual cell patterns, even though it has shown promise in patients with standard bladder cancer.
You likely qualify if…
You likely don't qualify if…
If you enroll, you would first receive chemotherapy to shrink the tumor. Then you would undergo the main trimodal therapy: a procedure to remove remaining cancer from your bladder, followed by chemotherapy and radiation therapy given at the same time to destroy any remaining cancer cells. Throughout the trial, you would have regular visits for imaging, blood work, and monitoring to track how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States